The system is designed to reduce unnecessary biopsies, lesion correlation time, and improve overall diagnostic accuracy.
Hologic, Inc., announced recently it has expanded its ultrasound product line with its first cart-based system – the SuperSonic™ MACH 40.
The new system, which has multi-touch trackpad called SonicPad™, company officials said, is designed to enhance efficiency and accuracy while providing high-quality images and standard-setting imaging modes.
“With the addition of the SuperSonic MACH 40 system, we’ve successfully built a comprehensive portfolio of innovative, standard-setting breast ultrasound solutions designed to better meet the needs of breast imagers,” said Pete Valenti, Hologic’s division president of breast and skeletal health solutions. “The SuperSonic MACH 40 system embodies our commitment to delivering future-oriented solutions and was designed to help healthcare professionals reduce unnecessary biopsies by eliminating re-scans, reducing lesion correlation time, and improving overall diagnostic accuracy.”
According to company information, this system includes several new features:
When conducting ultrasound-guided biopsies, company officials said, clinicians using the system can use Needle P.L.U.S. imaging to see both the biopsy needles and anatomical structures in real time, allowing them to predict needle trajectory.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.